Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin

Infect Dis Clin North Am. 2004 Sep;18(3):651-68, x. doi: 10.1016/j.idc.2004.04.014.

Abstract

An overview of the mechanism of action, dosing, clinical indications, and toxicities of the glycopeptide vancomycin is provided. Emerging gram-positive bacterial resistance to antimicrobials and its mechanisms are reviewed. Strategies to control emergence of resistance are proposed. Newer antimicrobial agents with activity against vancomycin-resistant organisms are now available and play a critical role in the treatment of life-threatening infections.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Daptomycin / pharmacology*
  • Daptomycin / therapeutic use
  • Gram-Positive Bacterial Infections / drug therapy*
  • Humans
  • Vancomycin / pharmacology*
  • Virginiamycin / pharmacology*
  • Virginiamycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Virginiamycin
  • quinupristin-dalfopristin
  • Vancomycin
  • Daptomycin